Medgenics Inc (NASDAQ:GNMX) – Equities researchers at Jefferies Group issued their FY2022 earnings per share (EPS) estimates for shares of Medgenics in a report issued on Tuesday. Jefferies Group analyst M. Andrews expects that the biotechnology company will earn ($1.39) per share for the year.

Shares of Medgenics (NASDAQ GNMX) traded down $0.12 during trading hours on Wednesday, hitting $2.27. The stock had a trading volume of 165,200 shares, compared to its average volume of 301,752. Medgenics has a one year low of $0.98 and a one year high of $6.18. The firm has a market cap of $141.80, a price-to-earnings ratio of -2.28 and a beta of 1.10.

Several large investors have recently made changes to their positions in the company. Northern Capital Management LLC grew its holdings in shares of Medgenics by 43.6% during the 3rd quarter. Northern Capital Management LLC now owns 152,300 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 46,250 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Medgenics by 433.7% during the 3rd quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 106,178 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Medgenics by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 78,400 shares in the last quarter. 16.57% of the stock is currently owned by institutional investors.

WARNING: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/02/14/fy2022-earnings-estimate-for-medgenics-inc-issued-by-jefferies-group-gnmx.html.

Medgenics Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.